Remove Blogging Remove Funding Remove Layoffs Remove Pricing
article thumbnail

Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More

Xconomy

military’s high-tech think tank DARPA described Safe Genes, a new program to fund safety measures that can be built into genome editing technology or counter its potential wayward effects. The funding could be as much as $100 million, and the first grants will be announced in 2017. PRICE FIGHTS. —The U.S.

article thumbnail

Biotech Roundup: Moonshots, Pink Slips, Gilead, Brexit & More

Xconomy

At the gathering, Biden took verbal shots at scofflaw cancer researchers and at drug prices, while the FDA said it would take a shot at restructuring the way it evaluates oncology products. Gilead Sciences has been a target of drug-price criticism for its hepatitis C treatments, but it dialed back the price of its new one.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More

Xconomy

In a week of big personnel moves, none was more surprising than Editas Medicine CEO Katrine Bosley’s departure.

Guide 63
article thumbnail

Bio Roundup: Senate Drama, A.I. Stories, Data Dives, Shkreli & More

Xconomy

There is no Obamacare replacement, at least not as of this writing. The Senate Republicans are fractured, with a handful of conservatives and moderates each giving a cold shoulder to their chamber’s version of healthcare reform, the Better Care Reconciliation Act.

Writing 56